Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianfei Tu

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
European Journal of Pharmacology|December 25, 2022
Inactivation of KDM5A suppresses growth and enhances chemosensitivity in liver cancer by modulating ROCK1/PTEN/AKT pathwayShiji Fang, Liyun Zheng, Lin Shen, et al.
Journal of Nanobiotechnology|April 3, 2022
Homogenous multifunctional microspheres induce ferroptosis to promote the anti-hepatocarcinoma effect of chemoembolizationMinjiang Chen, Jie Li, Gaofeng Shu, et al.
JAMA Oncology|July 10, 2025
Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: A Randomized Clinical TrialHan Xiao, Jiansong Ji, Shaoqiang Li, et al.
ACS Nano|March 11, 2024
Multiple Immunomodulatory Strategies Based on Targeted Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Immune Homeostasis against Hepatocellular CarcinomaShiji Fang, Liyun Zheng, Gao-Feng Shu, et al.
Hepatology International|July 17, 2023
MEX3A determines in vivo hepatocellular carcinoma progression and induces resistance to sorafenib in a Hippo-dependent wayShiji Fang, Liyun Zheng, Xiaoxiao Chen, et al.
Experimental Cell Research|January 23, 2017
Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancerMin Xu, Zhongwei Zhao, Jingjing Song, et al.
Lipids in Health and Disease|October 1, 2024
Glycerophospholipid-driven lipid metabolic reprogramming as a common key mechanism in the progression of human primary hepatocellular carcinoma and cholangiocarcinomaYanran Bi, Xihui Ying, Wanbin Chen, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 25, 2020
CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathwayZhongwei Zhao, Jingjing Song, Bufu Tang, et al.
Biomaterials Science|July 3, 2023
Recombinant supercharged polypeptides for safe and efficient heparin neutralizationJianfei Tu, Qing Liu, Shengye You, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|April 8, 2026
KAT2B inhibits cholangiocarcinoma proliferation by binding with histone demethylase KDM6BRongfang Qiu, Ziwei Xu, Hui Meng, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
European Journal of Pharmacology|December 25, 2022
Inactivation of KDM5A suppresses growth and enhances chemosensitivity in liver cancer by modulating ROCK1/PTEN/AKT pathwayShiji Fang, Liyun Zheng, Lin Shen, et al.
Journal of Nanobiotechnology|April 3, 2022
Homogenous multifunctional microspheres induce ferroptosis to promote the anti-hepatocarcinoma effect of chemoembolizationMinjiang Chen, Jie Li, Gaofeng Shu, et al.
JAMA Oncology|July 10, 2025
Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: A Randomized Clinical TrialHan Xiao, Jiansong Ji, Shaoqiang Li, et al.
ACS Nano|March 11, 2024
Multiple Immunomodulatory Strategies Based on Targeted Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Immune Homeostasis against Hepatocellular CarcinomaShiji Fang, Liyun Zheng, Gao-Feng Shu, et al.
Hepatology International|July 17, 2023
MEX3A determines in vivo hepatocellular carcinoma progression and induces resistance to sorafenib in a Hippo-dependent wayShiji Fang, Liyun Zheng, Xiaoxiao Chen, et al.
Experimental Cell Research|January 23, 2017
Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancerMin Xu, Zhongwei Zhao, Jingjing Song, et al.
Lipids in Health and Disease|October 1, 2024
Glycerophospholipid-driven lipid metabolic reprogramming as a common key mechanism in the progression of human primary hepatocellular carcinoma and cholangiocarcinomaYanran Bi, Xihui Ying, Wanbin Chen, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 25, 2020
CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathwayZhongwei Zhao, Jingjing Song, Bufu Tang, et al.
Biomaterials Science|July 3, 2023
Recombinant supercharged polypeptides for safe and efficient heparin neutralizationJianfei Tu, Qing Liu, Shengye You, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|April 8, 2026
KAT2B inhibits cholangiocarcinoma proliferation by binding with histone demethylase KDM6BRongfang Qiu, Ziwei Xu, Hui Meng, et al.
Pageof 11